李奧國際精準健康
LEO INTERNATIONAL PRECISION HEALTH

Building a global integrated AI-driven healthcare ecosystem

Börse Frankfurt (General Standard), Börse Düsseldorf
Ticker Symbol: LEOW

July 2026

Disclaimer And Forward-Looking Statements

This presentation and the information contained herein are provided for information purposes only. It does not constitute, and shall not be construed as, a prospectus, an offer to sell, or a solicitation of an offer to buy or subscribe for any securities of the Company within the meaning of the German Securities Trading Act (Wertpapierhandelsgesetz – WpHG), the EU Market Abuse Regulation (MAR), the German Stock Corporation Act (Aktiengesetz – AktG), or any other applicable securities laws. Nothing in this presentation shall form the basis of, or be relied upon in connection with, any contract, commitment, or investment decision.

This presentation may include forward-looking statements concerning the present or future financial condition, results of operations, business performance, or strategic outlook of the Company, its subsidiaries, or assets contributed by asset owners in connection with an injection in kind. These statements are based on current expectations, assumptions, and information available from internal and external sources. Such forward-looking statements are subject to risks and uncertainties, many of which are beyond the Company's control, and actual results may differ materially. The Company and its management expressly disclaim any obligation to update or revise such statements and accept no liability for any loss or damage, whether direct or indirect, arising from the use of, reliance on, or distribution of this presentation or its contents.

Financial and operational information presented herein, whether relating to the Company, its subsidiaries, or the asset owners, may be unaudited, incomplete, or preliminary, and is provided for reference only. For audited financial information, please refer to the respective statutory financial statements.

Nothing in this presentation shall be construed as superseding or amending the rights and obligations of the Company's executive management board (Vorstand) or supervisory board (Aufsichtsrat) under German corporate law.

EXECUTIVE SUMMARY

AI-Driven Precision Health Platform

李奧國際精準健康
LEO INTERNATIONAL PRECISION HEALTH

BUSINESS MODEL

Focus on acquiring and developing attractive opportunities, enhancing their value and selectively spinning them off, thereby generating shareholder value through **asset reconfiguration**, **revenue growth**, **licensing** and **royalties**.

INVESTMENT CASE

Built on
Innovation
Synergy
Scalability

- Listed in the General Standard at the **Frankfurt Stock Exchange** as well as the **Düsseldorf Stock Exchange** (ticker symbol: LEOW)
- Offering investors access to the expanding **Asian** and **global** healthcare and life sciences market.
- Strategic focus on AI-driven precision health assets across **Healthcare Services, MedTech**, **HealthTech** and **Biotech.**

CURRENT FLAGSHIP ASSETS

Dr. Pain | 100% holding

Chain of clinics offering integrated pain management with AI-driven rehabilitation solutions.

Pathomics Health | 67% holding

Advanced precision medicine and digital healthcare solutions for personalized prevention, diagnosis and treatment.

李奧國際精準健康
LEO INTERNATIONAL PRECISION HEALTH

LEADERSHIP

Experienced Team Bridging Science, Capital And Strategy

EXECUTIVE MANAGEMENT BOARD

SUPERVISORY BOARD



Data-Driven Healthcare Ecosystem Projects Vast Opportunity

MISSION

From molecule to market – creating sustainable precision health impact

The global AI healthcare market is projected to reach **US$ 868 billion** by 2030[1]

Healthcare is "below average" in its adoption of AI compared to other industries[4]

40% of new drug pipelines already AI-enabled[2]

30% of the world's data volume generated by the healthcare industry[3]

Rising demand for predictive, preventive, personalized medicine

AI ADOPTION IN HEALTHCARE
2025 vs. 2030[1]



1 PwC (2025): AI's US$ 868 billion healthcare revolution | Strategy& |
2 Deloitte (2024): us-advisory-generative-ai-regulation-in-life-sciences.pdf |
3 RBC Capital Markets (2023): https://www.rbccm.com/en/gib/healthcare/episode/the_healthcare_data_explosion |
4 World Economic Forum (2025): Industries in the Intelligent Age White Paper Series | World Economic Forum

李奧國際精準健康
LEO INTERNATIONAL PRECISION HEALTH

Structural Shifts Driving Growth

Rising demand through aging populations

- **By 2050,** 1 out of 6 will be 60 years or older[1]
- **By 2035,** chronic disease incidents will increase by more than 40%[1]
- **Healthcare systems under structural strain:** staff shortages, longer life expectancy, and greater chronic-care complexity

Escalating healthcare costs

- Global healthcare spending projected to surpass **USD 12 trillion by 2030**[2]
- **Traditional models are unsustainable:** reactive, siloed, and resource-intensive

Data explosion and fragmentation

- **Data trapped across diagnostics, clinics, and pharma R&D –** Low interoperability limits value creation

AI AS THE

Catalyst for efficiency and scale

Predictive analytics can reduce hospital readmissions by **up to 20–30%**[5]

AI-driven drug design cuts preclinical timelines by **up to 50%**[3]

AI triage and scheduling tools in clinics improve resource utilization **by >25%**[4]

OUTCOME

- Lower costs
- Faster innovation
- Scalable personalized care

1 UN (2024): World Population Prospects |
2 PwC (2025): AI's US$ 868 billion healthcare revolution | Strategy& |
3 BCC (2023): Unlocking the potential of AI in Drug Discovery – 2023 |
4 Desai (2025): AI in healthcare: Reducing processing costs and enhancing efficiency |
5 NIH (2020): Implementation of Artificial Intelligence-Based Clinical Decision Support to Reduce Hospital Readmissions at a Regional Hospital

Building Value Across The Full Precision Healthcare Continuum

CRITERIA

Mostly AI-driven with focus on innovation, synergy and scalability

INVESTMENT STRATEGY

- Acquire **profitable** healthcare services, medtech & healthtech **assets**
- Build **strong recurring cash flow** and **operational scale**
- **Reinvest cash flows** into next-generation **biotech assets** focusing on **oncology and precision-health innovation**
- **Long-term vision:** advance transformative cancer therapies and **improve patient outcomes globally**

4 complementary investment areas
that together cover the full continuum from discovery to patient care

1
HEALTHCARE SERVICES
Personalized care such as clinics and nutraceuticals

2
MEDTECH
Medical devices and diagnostics such as next-gen imaging, digital pathology

3
HEALTHTECH
Digital therapeutics and companions, software and predictive analytics

4
BIOTECH
Therapeutics and diagnostics such as liquid biopsy

INVESTMENT STRATEGY & PROCESS

Disciplined Origination of Scalable, AI-Driven Healthcare Assets

Continuous Sourcing, Selective Conversion

Origination & Screening

Shortlisting & Due Diligence

Active Investments

Listed & Private Assets
Engineered for Value Creation

Current Portfolio Valued at ~ EUR 111 million

TAIWAN

amiko AI

AI-driven software accelerating scientific discovery. Platform comprises Co-Scientist application for AI-assisted drug re-purposing and re-targeting.

54%

amiko AI

USA

Danner Lab

Clinical cytopathology laboratory testing for precision healthcare. High-growth liquid biopsy service with AI-assisted imaging analysis services using proprietary CellBio™ technology and developing systems.

51%

Danner Laboratory
A Clinical Laboratory Center of Excellence

HONG KONG

Dr PAIN (Wankang Medical Group)

Pain rehabilitation with clinics across Taiwan, Hong Kong and China. High-margin pain therapy and rehabilitation services with evolving AI diagnostics capabilities.

100%

Dr PAIN

TAIWAN

UHO Wellness (Immune Anima)

Nutraceuticals supporting standard of care cancer treatment. Core herbal products based on patented extraction process with 60%+ β-glucans concentration.

67%

uho 優活健康

SINGAPORE

Pathomics Health

Advanced precision medicine and digital healthcare solutions for personalized prevention, diagnosis and treatment. B2B partnerships with life insurance firms, banks, hospitals and pharma.

52%

Pathomics Health
Digitising Healthcare

AUSTRALIA

Renhe Biotech

Longevity and anti-aging health supplements including its NAD+ product line. Patent-protected formulations manufactured with GMP standards and Therapeutic Goods Administration (TGA) sales registration in Australia.

51%

人和生物
RENHE BIOTECH

VALUATION

Current Portfolio Companies

Asset	Shareholding
amiko AI	54%
Danner Laboratory, Inc	51%
Dr. PAIN	100%
UHO Wellness Corporation	67%
Pathomics Health Pte Ltd.	52%
Renhe Biotech Pty Ltd.	51%
Valuation of contribution in kind	**~EUR 111.0 M**

→

Transaction:

Acquisition of asset companies by way of capital increase against contributions in kind

Completion:	Dec 16, 2025
Share capital prior:	EUR 500,000.00
Share issuance:	50,000 new no-par value bearer shares
Share capital post:	EUR 550,000.00

Total value of portfolio companies ~ EUR 198.0 M

SYNERGY ENGINE

Turning Data, Science And Care Into Compounding Value

Synergies transform standalone assets into a **connected precision health ecosystem**

01
STRATEGIC
Linking AI and healthcare ecosystems

02
FINANCIAL
Co-investment & fund structuring to reconfigure and scale assets

03
OPERATIONAL
Shared AI, services and regulatory networks

04
MARKET
Cross-promotion and visibility across portfolio companies

Creating Shareholder Value by Adding Additional Nine Assets

Transaction scope
9 assets

Purchase price
EUR 400 -500M

EBITDA contribution
EUR 50 -60M

Acquisition of 9 companies across:

- Preventative care clinics & beauty clinics (such as Funnel Group)
- Healthcare platforms
- Biotechnology & medical products businesses

Geographic focus:

- Asia and Europe

Planned financing mix:

- Bank financing
- Listed corporate bond
- Shareholder loans

Strong cashflow contribution:

- Combining strong operational businesses
- Clear integration and synergy strategy
- Create a platform that is greater than the sum of its parts
- Contribute long-term growth and value creation to LIPH's

Intended acquisitions reflect our approach to building a high-quality, scalable portfolio of healthcare assets

Balance Sheet as of Dec 31, 2025

In EUR thousand	
Non-current assets	197,038
Intangible assets	*195,692*
Property, plant and equipment	*416*
Right-of-use assets (IFRS 16)	*661*
Deferred tax assets	*270*
Current financial assets	1,722
Total assets	198,760
Equity	172,868
Non-current liabilities	19,469
Current financial liabilities	6,424
Total equity and liabilities	198,760

The Group's financial position as of December 31, 2025, is primarily influenced by the initial contribution of the six portfolio companies as part of the capital increase through non-cash contributions in December 2025. Since the scope of consolidation was not established until the reporting date, the asset structure results primarily from the intangible assets identified and measured during the initial consolidation.

Intangible assets	In EUR thousand	Percentage of intangible assets
Goodwill	114,051	58%
Technologies	20,774	11%
Customer relationships	13,449	7%
Contractual rights	37,880	19%
Recipes	9,203	5%
Software	335	0%
Total	195,692	100 %

The Group's assets consist primarily of non-current assets, in particular goodwill and other intangible assets such as technologies and customer relationships, which were capitalized as part of the purchase price allocation for the acquired investments. There are no internally generated intangible assets.

Acquisition of asset companies by way of capital increase against contributions in kind

Completion:	Dec 16, 2025
Share issuance:	50,000 new no-par value bearer shares
Share capital post:	EUR 550,000.00

2026 Outlook and Guidance

Revenue	EBITDA	Liquidity
EUR 11 to 15 million	EUR (4) to (6) million	End of FY 2026

This revenue guidance is based on the planned revenues of the segments / assets as of Dec 31, 2025, only. It is based on a prudent assessment of organic business development and takes into account possible demand fluctuations, foreign exchange effects and the current integration status of the portfolio companies.

Operational development is expected to improve gradually, supported by economies of scale, increasing utilization of existing capacities and the ongoing implementation of synergy measures within the Group. The expected negative EBITDA result primarily reflects ongoing investments in the build-up of the Group structure, integration measures as well as central administrative and management functions.

Shares

Stock Information

Ticker symbol	LEOW
ISIN / WKN	DE0005490601 / 549060
Segment	General Standard
Share price (as of July 8, 2026)	EUR 19.00
52-week high-low	EUR 36.00 – 1.00
Shares issued	576,000
Market cap (as of July 8, 2026)	~EUR 11 million

Shareholder Structure

* Includes members of the Executive Management Board as well as the Supervisory Board and associated shareholders

Contact

www.liphag.com

Leo International Precision Health AG
Am Klopferspitz 19
82152 Planegg / Martinsried
Germany

Investor Relations &
Public Relations Contact

MC Services AG
LIPH@mc-services.eu

Leo International Precision Health AG
ir@liphag.com